MAPT and Alzheimer disease: Here, we provide a thorough analysis on the negligible association between OI ability and Aβ and CSF tau burden, from the limitation of the OI test and Aβ measures themselves (both are lack of specificity) and the drawbacks of currently averaging the Aβ levels for the whole brain, to the possible association between the pathologic development (amyloid plaques and tauopathy) and OI impairment based on the prion-like hypothesis in AD.